Nurture the mental health of your employees

The World Health Organization (WHO) reported depression as the leading cause of disability worldwide. deprexis® helps you support your employees in reducing symptoms of this disability.

Contact

Improve Employee Productivity

The World Health Organization (WHO) estimates that every $1 invested in treating depression results in a $4 return on productivity. By helping employees reduce their depressive symptoms, deprexis® enables employers to reduce direct and indirect losses due to workplace depression.

Reduce Total Business Compensations

By integrating directly into the care of your employee’s physician, deprexis® can help reduce your medical expenses on employee therapy sessions.

Tailored to the Needs of Your Company and Your Employees

Every employer and employee is different. That’s why deprexis® is highly personalized to specific needs and easily accessible on all internet-connected devices for independent use that integrates into everyday life.

Upgrade Your Benefits Package

Your employee-benefit package is instantly upgraded with deprexis®, empowering you to play a key role in nurturing the mental health of your employees.

Interested in deprexis®?

Contact

Real Science, Real Evidence

RCTs demonstrate deprexis®’ effectiveness, safety and suitability.

Effective Depression Treatment

Nine independent studies conducted with deprexis® have demonstrated its effectiveness as a standalone treatment and have confirmed the increase in benefits when deprexis® is added to existing care plans.

Bonnet et al. (2018) Zwerenz et al. (2017) Berger et al. (2017) Beevers et al. (2017) Klein et al. (2016) Meyer et al. (2015) Moritz et al. (2012) Berger et al. (2011) Meyer et al. (2009)

Effective Treatment of Comorbid Depression

Depression is especially prevalent in patients with severe medical conditions and disorders. deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.

Bücker et al. (2018) Fischer et al. (2015) Schröder et al. (2014)

Proven Cost Reduction

A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.

Gräfe et al. (2017)

Scientifically Replicated

Multiple meta-analyses and systematic reviews have confirmed the scientific evidence gathered in 13 RCTs that deprexis® is an effective treatment for depression.

Twomey et al. (2017) Rogers et al. (2017) Karyotaki et al. (2017) Johansson & Andersson (2012) Richards & Richardson (2012) Cuijpers et al. (2011)

Medical Research Network

USA: University of Texas, Austin; Cedars Sinai Medical Center Los Angeles; University of Massachusetts Medical School

SWEDEN: The Karolinska Institute; Linkoping University

GERMANY: Charite Universitätsmedizin Berlin; Universität Trier; Universität Tübingen

UK: University of Cambridge; Kings College London; City University, London

FUNDING PARTNERS: the U.S. department of veteran affairs, the U.S. national multiple sclerosis society, the European Union, the European Commission, the German ministry of health, and the Brain and Behavior Research Foundation, the German Association of Psychotherapists (DPTV), major German health insurance companies and several other research centers, universities and hospitals across Europe, the U.S. and other regions.

Interested in deprexis®?

Contact